Charles River Laboratories (NYSE: CRL) reported Q4 EPS of $1.49, $0.09 better than the analyst estimate of $1.40. Revenue for the quarter came in at $601.5 million versus the consensus estimate of $590.75 million.

James C. Foster, Chairman, President and Chief Executive Officer, said, “We believe our strong financial performance in 2018 and outlook for 2019 reflect continuing robust industry fundamentals and the benefit of actions we have taken to enhance our position as the leading early-stage CRO. By focusing on expanding our global scale and enhancing our scientific expertise, by improving our operating efficiency, and by providing a more seamless and flexible client experience, we are able to provide the individualized support which our clients require to expedite their drug research efforts and meet their extensive scientific needs.”

“The proposed acquisition of Citoxlab would be another strategic expansion of our portfolio. We believe this acquisition would further strengthen our Discovery and Safety Assessment business and enhance our ability to achieve our long-term growth goals,” Mr. Foster concluded.

GUIDANCE:

Charles River Laboratories sees FY2019 EPS of $6.25-$6.40, versus the consensus of $6.35.

For earnings history and earnings-related data on Charles River Laboratories (CRL) click here.